Advent International buys more than 50 per cent stake for Rs 6300 crore in this pharma company. Do you own it?
Advent International buys more than 50 per cent stake for Rs 6300 crore in this pharma company. Do you own it?

Advent International buys more than 50 per cent stake for Rs 6300 crore in this pharma company. Do you own it?

Advent is expected to buy 51 per cent of the promoter’s stake in the company and launch an open offer for an additional 26 per cent

Bhavya Rathod Article rating: 4.3

The company released a press release on Monday, stating Advent International has entered into definitive agreement to acquire significant stake in the company and intends to explore the merger of  its portfolio company

This pharma company received USDA approval for a generic drug which clocked over Rs 90 crore in sales, do you own it?
This pharma company received USDA approval for a generic drug which clocked over Rs 90 crore in sales, do you own it?

This pharma company received USDA approval for a generic drug which clocked over Rs 90 crore in sales, do you own it?

The company is ranked among the world’s top 100 biopharmaceutical companies and among the world’s top 50 companies in the off-patent sector.

Bhavya Rathod Article rating: 4.4

Glenmark Pharmaceuticals Ltd is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses

This pharma company stock went 8 per cent high, do you own it?
This pharma company stock went 8 per cent high, do you own it?

This pharma company stock went 8 per cent high, do you own it?

With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Kiran Shroff Article rating: 5.0

This pharma company stock went 8 per cent high, do you own it?                                                                                                                                                                                                       With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Upcoming collaboration: Two leading pharma company stocks to watch out for
Upcoming collaboration: Two leading pharma company stocks to watch out for

Upcoming collaboration: Two leading pharma company stocks to watch out for

US FDA approved a benzyl alcohol and propylene glycol-free formulation to minimize gasping syndrome risk, for the treatment of seizures in newborns

Kiran Shroff Article rating: 4.5

Upcoming collaboration: Two leading pharma company stocks to watch out for                                                                                                                                                                                            US FDA approved a benzyl alcohol and propylene glycol-free formulation to minimize gasping syndrome risk, for the treatment of seizures in newborns.

Shilpa Medicare skyrockets by 10.47 per cent on a weak market day!
Shilpa Medicare skyrockets by 10.47 per cent on a weak market day!

Shilpa Medicare skyrockets by 10.47 per cent on a weak market day!

The board of the company also has recommended a dividend of Rs 1.10 per equity share for the financial year ended March 31, 2022.  

Sayali Kotwal Article rating: 5.0

The shares of Shilpa Medicare soared 10.47 per cent to Rs 453.25 on BSE after the company announced promising results for the quarter that ended on March 31, 2022.

RSS

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR